Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma

Cancer

Volumn 118, Issue 22, 2012, Pages 5698-5708

  Jain, Meenu ^a   Zhang, Lisa ^a   He, Mei ^a   Patterson, Erin E ^a   Nilubol, Naris ^a   Fojo, Antonio T ^a   Joshi, Bharat ^b   Puri, Raj ^b   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

adrenocortical carcinoma; interleuken 13 Pseudomonas exotoxin; interleukin 13 receptor alpha2; invasion

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN; INTERLEUKIN 13 RECEPTOR ALPHA2; MESSENGER RNA; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; FUNCTIONAL ASSESSMENT; GENE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IL13RALPHA2 GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR NECROSIS;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; EXOTOXINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868211851     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27629     Document Type: Article

References (40)

1. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008; 113: 3130-3136.
2. Icard P, Louvel A, Le Charpentier M, Chapuis Y,. [Adrenocortical tumors with oncocytic cells: benign or malignant?] Ann Chir. 2001; 126: 249-253.
3. Favia G, Lumachi F, Carraro P, D'Amico DF,. Adrenocortical carcinoma. Our experience. Minerva Endocrinol. 1995; 20: 95-99.
4. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000; 88: 711-736.
5. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A,. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006; 30: 872-878.
6. Lombardi CP, Raffaelli M, Pani G, et al. Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study. Biomed Pharmacother. 2006; 60: 86-190.
7. Slater EP, Diehl SM, Langer P, et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol. 2006; 154: 587-598.
8. Velazquez-Fernandez D, Laurell C, Geli J, et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery. 2005; 138: 1087-1094.
9. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003; 162: 521-531.
10. Fernandez-Ranvier GG, Weng J, Yeh RF, et al. Identification of biomarkers of adrenocortical carcinoma using genome wide gene expression profiling. Arch Surg. 2008; 143: 841-846; discussion 846.
11. Suh I, Guerrero MA, Kebebew E,. Gene-expression profiling of adrenocortical carcinoma. Expert Rev Mol Diagn. 2009; 9: 343-351.
12. Husain SR, Obiri NI, Gill P, et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res. 1997; 3: 151-156.
13. Joshi BH, Leland P, Puri PK,. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-Pseudomonas exotoxin fusion protein. Croat Med J. 2003; 44: 455-462.
14. Kawakami M, Kawakami K, Kasperbauer JL, et al. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res. 2003; 9: 6381-6388.
15. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood. 1996; 87: 4333-4339.
16. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK,. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer. 2006; 107: 1407-1418.
17. Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK,. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res. 2010; 16: 577-586.
18. Kioi M, Shimamura T, Nakashima H, et al. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer. 2009; 124: 1440-1448.
19. Kawakami K, Taguchi J, Murata T, Puri RK,. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood. 2001; 97: 2673-2679.
20. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ,. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 2002; 62: 1103-1109.
21. O'shea JJ, Gadina M, Schreiber RD,. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109 (suppl): S121-S131.
22. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A,. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006; 12: 99-106.
23. Wynn TA,. IL-13 effector functions. Annu Rev Immunol. 2003; 21: 425-456.
24. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ,. Immunotoxin treatment of cancer. Annu Rev Med. 2007; 58: 221-237.
25. Joshi BH, Puri RK,. Optimization of expression and purification of 2 biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif. 2005; 39: 189-198.
26. Joshi BH, Kawakami K, Leland P, Puri RK,. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res. 2002; 8: 1948-1956.
27. Kioi M, Seetharam S, Puri RK,. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther. 2008; 7: 1579-1587.
28. Fujisawa T, Joshi B, Nakajima A, Puri RK,. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 2009; 69: 8678-8685.
29. Joshi BH, Plautz GE, Puri RK,. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 2000; 60: 1168-1172.
30. Debinski W, Gibo DM,. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med. 2000; 6: 440-449.
31. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol. 1997; 15: 535-541.
32. Johnsen M, Lund LR, Romer J, Almholt K, Dano K,. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 1998; 10: 667-671.
33. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436: 518-524.
34. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002; 62: 3335-3339.
35. Sutherland RM, McCredie JA, Inch WR,. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst. 1971; 46: 113-120.
36. Mueller-Klieser W,. Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol. 2000; 36: 123-139.
37. Vogelbaum MA, Sampson JH, Kunwar S, et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery. 2007; 61: 1031-1037; discussion 1037-1038.
38. Keppler-Hafkemeyer A, Brinkmann U, Pastan I,. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry. 1998; 37: 16934-16942.
39. Hafkemeyer P, Brinkmann UE, Gottesman MM, Pastan I,. Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. Hum Gene Ther. 2000; 10: 923-934.
40. Kawakami M, Kawakami K, Puri RK,. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol Immunother. 2002; 50: 691-700.